SG45147A1 - Combination of a cholestrol biosynthesis inhibitor and a b-lactam cholestrol absorption inhibitor - Google Patents

Combination of a cholestrol biosynthesis inhibitor and a b-lactam cholestrol absorption inhibitor

Info

Publication number
SG45147A1
SG45147A1 SG1996000543A SG1996000543A SG45147A1 SG 45147 A1 SG45147 A1 SG 45147A1 SG 1996000543 A SG1996000543 A SG 1996000543A SG 1996000543 A SG1996000543 A SG 1996000543A SG 45147 A1 SG45147 A1 SG 45147A1
Authority
SG
Singapore
Prior art keywords
cholestrol
inhibitor
pct
combination
lactam
Prior art date
Application number
SG1996000543A
Other languages
English (en)
Inventor
Harry R Davis
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of SG45147A1 publication Critical patent/SG45147A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
SG1996000543A 1992-12-23 1993-12-21 Combination of a cholestrol biosynthesis inhibitor and a b-lactam cholestrol absorption inhibitor SG45147A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99548892A 1992-12-23 1992-12-23

Publications (1)

Publication Number Publication Date
SG45147A1 true SG45147A1 (en) 1998-01-16

Family

ID=25541876

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996000543A SG45147A1 (en) 1992-12-23 1993-12-21 Combination of a cholestrol biosynthesis inhibitor and a b-lactam cholestrol absorption inhibitor

Country Status (32)

Country Link
US (1) US5661145A (fr)
EP (1) EP0675714B1 (fr)
JP (1) JP3992728B2 (fr)
KR (1) KR100306936B1 (fr)
CN (1) CN1090479C (fr)
AT (1) ATE175872T1 (fr)
AU (1) AU680864B2 (fr)
CA (1) CA2152351C (fr)
CZ (1) CZ287125B6 (fr)
DE (1) DE69323213T2 (fr)
DK (1) DK0675714T3 (fr)
EE (1) EE03383B1 (fr)
ES (1) ES2128552T3 (fr)
FI (1) FI952916L (fr)
GR (1) GR3029405T3 (fr)
HR (1) HRP931515B1 (fr)
HU (1) HU221724B1 (fr)
IL (1) IL108112A (fr)
LT (1) LT3300B (fr)
LV (1) LV10919B (fr)
MX (1) MX9308053A (fr)
MY (1) MY109538A (fr)
NO (1) NO311325B1 (fr)
NZ (1) NZ259790A (fr)
PL (1) PL174128B1 (fr)
SG (1) SG45147A1 (fr)
SI (1) SI9300677A (fr)
SK (1) SK281173B6 (fr)
TW (1) TW319698B (fr)
WO (1) WO1994014433A1 (fr)
YU (1) YU49060B (fr)
ZA (1) ZA939552B (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AU2453295A (en) * 1994-09-20 1996-04-19 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
AU720853B2 (en) 1995-11-02 2000-06-15 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
AR023463A1 (es) 1999-04-16 2002-09-04 Schering Corp Uso de compuestos de azetidinona
EP1192963A4 (fr) * 2000-04-05 2004-08-25 Toray Industries Adsorbants pour proteines de la famille hmg et colonne de purification de liquide organique
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
DK1355644T3 (da) 2001-01-26 2006-10-23 Schering Corp Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
HU230253B1 (hu) 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
EP1911462A3 (fr) 2001-01-26 2011-11-30 Schering Corporation Combinaisons comprenant un inhibiteur d'absorption de stérol
CN101297969B (zh) * 2001-01-26 2011-03-09 先灵公司 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药
DK1373230T3 (da) 2001-03-28 2005-11-07 Schering Corp Enantiselektiv syntese af azetidinon mellemprodukter
JP2005504091A (ja) * 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
AU2002335770B2 (en) * 2001-09-21 2005-08-18 Merck Sharp & Dohme Corp. Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
AU2002348276A1 (en) 2001-11-16 2003-06-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
DE10227508A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
EP1560488B1 (fr) 2002-11-05 2010-09-01 Glaxo Group Limited Agents antibacteriens
WO2004043457A1 (fr) 2002-11-06 2004-05-27 Schering Corporation Inhibiteurs d'absorption de cholesterol pour le traitement de troubles auto-immuns
EP1810971B1 (fr) * 2003-03-07 2013-12-25 Merck Sharp & Dohme Corp. Composés d'azetidinone substitués, formulations et utilisations de ceux-ci pour traiter l'hypercholestérolémie
JP4589919B2 (ja) * 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
CA2517571C (fr) * 2003-03-07 2011-07-05 Schering Corporation Azetidinones substituees , procedes pour leur preparation, formulations et utilisations de celles-ci
JP2006519869A (ja) * 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
GB2423927A (en) * 2003-08-29 2006-09-13 Cotherix Inc Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1918000A2 (fr) 2003-11-05 2008-05-07 Schering Corporation Combinaisons d'agents de modulation lipide et azétidinones substitués et traitements pour conditions vasculaires
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
AU2004308332B2 (en) * 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
ATE485267T1 (de) 2003-12-23 2010-11-15 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
JP4590417B2 (ja) * 2004-01-16 2010-12-01 メルク・シャープ・エンド・ドーム・コーポレイション Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法
EP3269713A1 (fr) * 2004-07-01 2018-01-17 OPKO Health, Inc. Dérivés de pipéridine en tant qu'antagonistes nk1
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
US20060154959A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and carvedilol
EP1807070A1 (fr) * 2004-09-29 2007-07-18 Schering Corporation Combinaisons d'azetidinones substituees et d'antagonistes cb1
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2006076598A2 (fr) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Composes heterocycliques bicycliques en tant que modulateurs des recepteurs de canabinoides
US7368458B2 (en) 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076569A2 (fr) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Heterocycles bicycliques servant de modulateurs aux recepteurs cannabinoides
US20070141174A1 (en) * 2005-01-13 2007-06-21 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
EP1846410B1 (fr) 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydroquinazolinones utilisees comme modulateurs de la 5ht
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
TW200738676A (en) * 2005-06-20 2007-10-16 Schering Corp Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR057072A1 (es) * 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US20070105817A1 (en) * 2005-11-09 2007-05-10 Jim Page Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
AU2006331770A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US7910698B2 (en) * 2006-02-24 2011-03-22 Schering Corporation NPC1L1 orthologues
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
US20080103122A1 (en) * 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
JP2010514841A (ja) * 2007-01-03 2010-05-06 グレン ブイ． コルネット， 肺疾患および心疾患の処置におけるシクレタニンおよびｐｋｃ阻害剤
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
MX2011009852A (es) 2009-03-27 2011-09-29 Bristol Myers Squibb Co Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv.
EP2892896B1 (fr) 2012-09-05 2016-06-29 Bristol-Myers Squibb Company Antagonistes du récepteur 1 de l'hormone de concentration de pyrrolone ou pyrrolidinone mélanine
US9499482B2 (en) 2012-09-05 2016-11-22 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
MA53175A (fr) 2018-07-19 2021-05-26 Astrazeneca Ab Méthodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci
AU2022291768A1 (en) 2021-06-16 2023-11-30 Celgene Corporation Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5085473A (en) * 1990-10-09 1992-02-04 Yuhe Yang Air actuated car curtain device
JP2525125B2 (ja) 1991-07-23 1996-08-14 シェリング・コーポレーション 血清コレステロ―ル低下薬として有用な置換β−ラクタム化合物およびそれらの製法
PT2807099T (pt) 2012-01-26 2017-02-08 Intralot Sa Integrated Lottery Systems & Services Métodos e sistemas para dispensa e tiragem

Also Published As

Publication number Publication date
IL108112A (en) 1999-11-30
FI952916A7 (fi) 1995-06-14
CN1095591A (zh) 1994-11-30
FI952916A0 (fi) 1995-06-14
JPH08505141A (ja) 1996-06-04
DK0675714T3 (da) 1999-09-13
CZ287125B6 (en) 2000-09-13
EE9400341A (et) 1996-04-15
JP3992728B2 (ja) 2007-10-17
ATE175872T1 (de) 1999-02-15
MX9308053A (es) 1994-06-30
NO311325B1 (no) 2001-11-19
PL174128B1 (pl) 1998-06-30
CN1090479C (zh) 2002-09-11
TW319698B (fr) 1997-11-11
ZA939552B (en) 1994-10-12
HRP931515A2 (en) 1996-12-31
YU49060B (sh) 2003-08-29
LT3300B (en) 1995-06-26
GR3029405T3 (en) 1999-05-28
IL108112A0 (en) 1994-04-12
NZ259790A (en) 1997-02-24
NO952529L (no) 1995-06-23
US5661145A (en) 1997-08-26
HU9501854D0 (en) 1995-08-28
LTIP1514A (en) 1994-10-25
AU680864B2 (en) 1997-08-14
LV10919B (en) 1996-04-20
SI9300677A (en) 1994-09-30
DE69323213D1 (de) 1999-03-04
CA2152351A1 (fr) 1994-07-07
AU5872094A (en) 1994-07-19
EE03383B1 (et) 2001-04-16
PL309636A1 (en) 1995-10-30
HU221724B1 (hu) 2002-12-28
NO952529D0 (no) 1995-06-23
ES2128552T3 (es) 1999-05-16
HUT72081A (en) 1996-03-28
FI952916L (fi) 1995-06-14
SK78395A3 (en) 1996-05-08
HRP931515B1 (en) 2000-02-29
CA2152351C (fr) 2009-09-22
YU80293A (sh) 1997-12-05
WO1994014433A1 (fr) 1994-07-07
SK281173B6 (sk) 2000-12-11
EP0675714A1 (fr) 1995-10-11
DE69323213T2 (de) 1999-07-08
KR100306936B1 (ko) 2001-11-30
MY109538A (en) 1997-02-28
EP0675714B1 (fr) 1999-01-20
CZ164395A3 (en) 1996-03-13
LV10919A (lv) 1995-12-20

Similar Documents

Publication Publication Date Title
SG45147A1 (en) Combination of a cholestrol biosynthesis inhibitor and a b-lactam cholestrol absorption inhibitor
GEP20033006B (en) Sugar-Substituted 2-Azetidinones Useful as Hypocholesterolemic Agents
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
WO1996009827A3 (fr) Combinaison d'un inhibiteur d'absorption du cholesterol et d'un inhibiteur de synthese du cholesterol
UA37201C2 (uk) Композиція, що сприяє зниженню потреби людини у палінні тютюну, спосіб, що сприяє зниженню потреби людини у палінні тютюну (варіанти), та спосіб заміни паління тютюну (варіанти)
AU6008894A (en) Hypolipidaemic compounds
GR3025014T3 (en) A pharmaceutical composition for the intranasal administration of hydroxocobalamin
ZA931318B (en) Method of treatment
AU4923093A (en) Inhibitors of metazoan parasite proteases
GB9514821D0 (en) Galanthamine derivatives
MX9701816A (es) Cepas de bacterias y composicion farmaceutica que contiene dichas cepas y uso de la misma para prevenir y tratar enfermedades asociadas con el metabolismo alterado de acidos biliares o causadas por el mismo.
GB9509321D0 (en) Methods of and substances for inhibiting oxidative enzymes
IL125821A0 (en) A pharmaceutical composition containing dehydroepiandrosterone and aromatase inhibitors and use thereof
AU2982495A (en) Heterocycle-condensed morphinoid derivatives
WO2000038620A3 (fr) Composition utile pour traiter la parodontopathie
AU2961199A (en) Hiv cofactor inhibitors and medicinal compositions for preventing or treating hiv-infection
EP0674521A4 (fr) PROCEDE DE TRAITEMENT DE PROSTATITE CHRONIQUE AVEC DES 17-g(b)-CARBAMOYL-N-MONOSUBSTITUE-4-AZA-5-g(a)-ANDROST-1-EN-3-ONES.
DE69717277D1 (en) Imidazopyridine
AU9294698A (en) Methods and compositions for enhanced wound healing
AU3347193A (en) Fungicidal compositions
AU5625194A (en) Rectal flunisolide compositions for treating inflammatory intestinal disorders
UA41376C2 (uk) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЛІКУВАННЯ АНДРОГЕННОЇ АЛОПЕЦІЇ ІНГІБІТОРАМИ 5-<font face="Symbol">a</font>-РЕДУКТАЗИ
CA2135712A1 (fr) L'activite synergique du glutaraldehyde en presence d'oxydants